Venrock Healthcare Capital Par Purchases 43,707 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $8.76 per share, with a total value of $382,873.32. Following the completion of the acquisition, the insider now directly owns 4,986,480 shares of the company’s stock, valued at $43,681,564.80. This represents a 0.88 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The shares were bought at an average price of $9.22 per share, with a total value of $134,261.64.

KalVista Pharmaceuticals Stock Up 1.5 %

NASDAQ KALV opened at $9.90 on Thursday. The firm has a market cap of $489.26 million, a P/E ratio of -2.72 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $16.88. The business’s 50-day moving average price is $8.80 and its 200 day moving average price is $10.77.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.01. As a group, analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the period. HighVista Strategies LLC raised its holdings in KalVista Pharmaceuticals by 4.5% during the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after purchasing an additional 1,432 shares in the last quarter. JPMorgan Chase & Co. lifted its position in KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after purchasing an additional 1,670 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,043 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently commented on KALV shares. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. JMP Securities started coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, TD Cowen initiated coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).